Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxagliptin for CFRD Prevention
NCT02239458Unknown
- Start
- Jun 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in cystic fibrosis-related diabetes (CFRD) comparing Saxagliptin 5mg with Placebo (2 arms). Primary endpoint: Oral Disposition Index at 3 months. Status: unknown.
02
Drugs
saxagliptin
03
Conditions
cystic fibrosis-related diabetes (CFRD)
Beyond the preview
Go deeper on NCT02239458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02239458.